Cost-Effectiveness Analysis of Oral Direct-Acting Antivirals for Chinese Patients with Chronic Hepatitis C
Authors:
- 19 November 2020
- journal article
- research article
- Published by Springer Nature in Applied Health Economics and Health Policy
- Vol. 19 (3) , 371-387
Abstract
Background and Objective All oral direct-acting antivirals (DAAs) have shown excellent efficacy and safety in Chinese patients with chronic hepatitis C (CHC). However, the cost of DAAs used to be expensive; therefore, large numbers of patients had no access to DAAs in China. Recently, prices have been greatly reduced. The objective of this study was to evaluate the cost-effectiveness of ledipasvir/sofosbuvir (LDV/SOF), sofosbuvir/velpatasvir (SOF/VEL), elbasvir/grazoprevir (EBR/GZR) and glecaprevir/pibrentasvir (GLE/PIB) in Chinese CHC patients stratified by hepatitis C virus (HCV) genotype (GT), cirrhosis status, and treatment history. Methods On the basis of a Chinese healthcare perspective, a Markov model was constructed to estimate the lifetime costs and health outcomes of patients treated with different DAA regimens. Chinese-specific clinical, cost, and utility inputs were obtained or calculated from published sources and expert opinions. Costs, life-years (LYs), quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios (ICERs) were reported as primary outcomes. Base-case analysis and sensitivity analysis were conducted. Results At a willing-to-pay (WTP) threshold of US$30,081/QALY (calculated by three times the GDP per capita in China), SOF/VEL was cost-effective in patients with HCV GT 1, 3, and 6 infections, and the probabilities that SOF/VEL was cost-effective were 9.7–75.7%, 39.1–63.9%, and 35.6–88.0%, respectively. For GT2 patients, noncirrhotic patients, treatment-naïve patients, and treatment-experienced patients, LDV/SOF was the most cost-effective regimen, and the probabilities of cost-effectiveness for each of these groups was 92.1–99.8%, 89.9–99.0%, 61.6–91.2%, and 99.3–100.0%, respectively below the WTP threshold. The GLE/PIB regimen (12-week duration) was the most cost-effective in cirrhotic patients, whereas the probability of its cost-effectiveness varied with that of EBR/GZR (4.1–93.8% versus 6.2–93.3%) below the WTP threshold. Conclusions Overall, SOF/VEL and LDV/SOF regimens are more likely to be cost-effective among various subgroups of Chinese patients with CHC.Keywords
This publication has 28 references indexed in Scilit:
- Distribution and clinical correlates of viral and host genotypes in Chinese patients with chronic hepatitis C virus infectionJournal of Gastroenterology and Hepatology, 2013
- A Novel Estimation of the Impact of Treatment with Entecavir on Long-Term Mortality, Morbidity, and Health Care Costs of Chronic Hepatitis B in ChinaValue in Health Regional Issues, 2013
- Eradication of Hepatitis C Virus Infection and the Development of Hepatocellular CarcinomaAnnals of Internal Medicine, 2013
- Association Between Sustained Virological Response and All-Cause Mortality Among Patients With Chronic Hepatitis C and Advanced Hepatic FibrosisJAMA, 2012
- Structural Frameworks and Key Model Parameters in Cost-Effectiveness Analyses for Current and Future Treatments of Chronic Hepatitis CValue in Health, 2011
- All-Cause, Liver-Related, and Non-Liver-Related Mortality Among HCV-Infected Individuals in the General US PopulationClinical Infectious Diseases, 2011
- Estimation of stage‐specific fibrosis progression rates in chronic hepatitis C virus infectionHepatology, 2008
- The Impact of Chronic Hepatitis B on Quality of Life: A Multinational Study of Utilities from Infected and Uninfected PersonsValue in Health, 2008
- Long term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon monotherapyGut, 2004
- Morbidity and mortality in compensated cirrhosis type C: A retrospective follow-up study of 384 patientsGastroenterology, 1997